Bio-Thera And Intract Partner For Oral mAb Project

Chinese Biosimilars Specialist Licenses Soteria And Phloral Drug Delivery Technologies

Chinese biosimilars specialist Bio-Thera Solutions has struck a licensing deal with Intract Pharma that will give it access to drug delivery technologies that will be used to develop novel oral monoclonal antibody treatments for gastrointestinal inflammatory indications.

Monoclonal antibodies mabs
Bio-Thera will use Intract’s technology to develop novel oral mAbs • Source: Alamy

More from Biosimilars

More from Products